According to a recent LinkedIn post from OpenEvidence, the company is highlighting a strategic partnership with Wiley aimed at integrating Wiley’s scientific and medical content into the OpenEvidence platform. The post notes that Wiley’s corpus includes the Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, and material from more than 400 peer‑reviewed journals and medical references across multiple specialties.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that this integration is intended to make Wiley’s content more accessible at the point of clinical decision‑making within OpenEvidence’s workflow tools. A quote attributed to Wiley’s president and CEO, Matthew Kissner, indicates an expectation that bringing this portfolio into OpenEvidence could support physicians in making more informed decisions for patients.
For investors, the partnership may indicate an effort by OpenEvidence to deepen its product differentiation through exclusive or premium content relationships in evidence‑based medicine. Access to a large, reputable library of peer‑reviewed material could enhance perceived platform value, potentially improving user acquisition, engagement, and retention among clinicians and healthcare institutions.
The post also implies that Wiley is extending the reach of its content into AI‑enabled or decision‑support environments, which could strengthen Wiley’s positioning in digital health and clinical information markets. If the collaboration scales successfully, it could create recurring licensing or revenue‑sharing opportunities and increase switching costs for OpenEvidence’s customers, reinforcing its competitive moat within clinical decision support and medical AI tools.